Holen Sie sich die Stockscreener-App
26.71
0.45%
0.12
Handel nachbörslich:
26.71
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis at Guggenheim Summit: Strategic Growth and Market Expansion By Investing.com - Investing.com Canada
Arcutis Biotherapeutics Touts ZORYVE Expansion, New Indications and 2026 Cash-Flow Breakeven Goal - MarketBeat
Have Insiders Sold Arcutis Biotherapeutics Shares Recently? - simplywall.st
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Shows High-Growth Momentum and Strong Technical Setup - ChartMill
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: A Promising 18.12% Upside Potential for Investors - DirectorsTalk Interviews
Implied Volatility Surging for Arcutis Biotherapeutics Stock Options - Yahoo Finance
This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit - AOL.com
Can Arcutis Biotherapeutics Inc sustain earnings growthWeekly Investment Summary & Consistent Profit Alerts - baoquankhu1.vn
Pullback Watch: What is the PEG ratio of Arcutis Biotherapeutics Inc2025 Earnings Surprises & Weekly Top Stock Performers List - baoquankhu1.vn
Trading the Move, Not the Narrative: (ARQT) Edition - Stock Traders Daily
Positive Infant Trial Data For ZORYVE Might Change The Case For Investing In Arcutis Biotherapeutics (ARQT) - Yahoo Finance
Baron Health Care Fund is Expecting High Operating Margins for Arcutis Biotherapeutics (ARQT) - Insider Monkey
Baron Health Care Fund: Expecting High Operating Margins for Arcutis Biotherapeutics (ARQT) - Yahoo Finance UK
Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule - marketscreener.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Arcutis Biotherapeutics CEO Watanabe sells $505,709 in ARQT stock By Investing.com - Investing.com Canada
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 40,638 Shares of Stock - MarketBeat
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Bioth - GuruFocus
Edwards Larry Todd sells Arcutis Biotherapeutics shares for $52,322 By Investing.com - Investing.com Canada
Arcutis Biotherapeutics EVP Burnett sells $346,453 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics EVP Burnett sells $346,453 in stock - Investing.com
Arcutis Biotherapeutics director Welgus sells $250k in shares By Investing.com - Investing.com Canada
Arcutis Biotherapeutics CFO Vairavan sells $33657 in stock By Investing.com - Investing.com Canada
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Sells $33,660.00 in Stock - MarketBeat
Todd Watanabe Sells 19,833 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 10,000 Shares - MarketBeat
Larry Todd Edwards Sells 2,052 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Patrick Burnett Sells 3,675 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics CFO Vairavan sells $33657 in stock - Investing.com
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Exploring a 24% Upside Potential in the Booming Biotech Sector - DirectorsTalk Interviews
Aug Sectors: Is Arcutis Biotherapeutics Inc stock good for income investorsJuly 2025 Weekly Recap & Verified Trade Idea Suggestions - baoquankhu1.vn
Arcutis reports positive results for eczema cream in infants By Investing.com - Investing.com Nigeria
Arcutis reports positive phase 2 data for roflumilast cream (Zoryve) in infants with atopic dermatitis - Contemporary Pediatrics
Arcutis Biotherapeutics (ARQT) Reports Positive Phase 2 Trial Re - GuruFocus
Arcutis reports positive results for eczema cream in infants - Investing.com
Arcutis Biotherapeutics Reports Positive Phase 2 Results for ZORYVE Cream 0.05% in Infants with Atopic Dermatitis - Quiver Quantitative
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis - The Manila Times
Infant eczema cream helped 58% of patients in 4-week Arcutis study - Stock Titan
Tejara Capital Ltd Sells 352,878 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Published on: 2026-01-30 11:27:41 - baoquankhu1.vn
AI Stocks: What are analysts price targets for Arcutis Biotherapeutics Inc2025 Major Catalysts & Risk Managed Trade Strategies - baoquankhu1.vn
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: A Promising Biotech Play with 20.63% Potential Upside - DirectorsTalk Interviews
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa - Yahoo Finance
Growth Review: Can Arcutis Biotherapeutics Inc stock outperform in a bear marketWeekly Profit Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Arcutis terminates promotion agreement with Kowa for ZORYVE By Investing.com - Investing.com Nigeria
(ARQT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Swing Trade: Is Alaunos Therapeutics Inc a turnaround story2025 Price Targets & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Arcutis Biotherapeutics (ARQT) Sees Target Price Boost from Needham | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Arcutis Terminates Promotion Agreement for Zoryve With Kowa Pharmaceuticals America - marketscreener.com
Arcutis terminates promotion agreement with Kowa for ZORYVE - Investing.com
Arcutis Biotherapeutics (ARQT) Takes Over ZORYVE Promotion - GuruFocus
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):